Literature DB >> 2125733

Evidence of the selective alteration of anthracycline activity due to modulation by ICRF-187 (ADR-529).

M D Green1, P Alderton, J Gross, F M Muggia, J L Speyer.   

Abstract

Anthracyclines are powerful anticancer drugs whose use is limited by the development of chronic cardiotoxicity. The bisdioxopiperazine compound ICRF-187 (ADR-529) specifically abrogates this toxicity both in preclinical animal models and in humans. It does this without effecting either the acute toxicities or the anticancer activity. Therefore, with a specific antagonist, the mechanism of activity of the anthracyclines can be explored. This review discusses recent clinical trials and animal models addressing this issue and concludes by hypothesizing a mechanism of action.

Entities:  

Mesh：

Substances：

Year:  1990        PMID： 2125733     DOI： 10.1016/0163-7258(90)90018-w

Source DB:  PubMed          Journal:  Pharmacol Ther        ISSN： 0163-7258            Impact factor:   12.310


  6 in total

1.  Preventing the cardiotoxicity of anthracyclines by dexrazoxane.

Authors:  K Hellmann
Journal:  BMJ       Date:  1999-10-23

Review 2.  Anthracyclines and the heart.

Authors:  W Rhoden; P Hasleton; N Brooks
Journal:  Br Heart J       Date:  1993-12

Review 3.  The role of active metabolites in drug toxicity.

Authors:  M Pirmohamed; N R Kitteringham; B K Park
Journal:  Drug Saf       Date:  1994-08       Impact factor: 5.606

4.  Monohydroxyethylrutoside as protector against chronic doxorubicin-induced cardiotoxicity.

Authors:  S A van Acker; K Kramer; J A Grimbergen; D J van den Berg; W J van der Vijgh; A Bast
Journal:  Br J Pharmacol       Date:  1995-08       Impact factor: 8.739

5.  Modulation of the in vitro cardiotoxicity of doxorubicin by flavonoids.

Authors:  B C Hüsken; J de Jong; B Beekman; R C Onderwater; W J van der Vijgh; A Bast
Journal:  Cancer Chemother Pharmacol       Date:  1995       Impact factor: 3.333

6.  A comparative study between catalase gene therapy and the cardioprotector monohydroxyethylrutoside (MonoHER) in protecting against doxorubicin-induced cardiotoxicity in vitro.

Authors:  M A I Abou-El-Hassan; M J W E Rabelink; W J F van der Vijgh; A Bast; R C Hoeben
Journal:  Br J Cancer       Date:  2003-12-01       Impact factor: 7.640
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.